A Practical Guide for Wegovy Users, From First Injection to Long-Term Progress

Step 1: Understanding why the dose starts so low

The first thing that surprises many people is that Wegovy begins at 0.25 mg, a dose that produces very little appetite change. That is deliberate. The starting dose is there to let your digestive system adjust to the medicine before the therapeutic doses arrive. Jumping to a higher strength too quickly is one of the most reliable ways to trigger prolonged nausea, so the slow climb exists to protect you from it.

Over the first four months or so, a prescriber will move the dose through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance level. The MHRA has also approved a higher 7.2 mg dose (first as three 2.4 mg pens weekly, then as a dedicated single-dose pen approved in April 2026) for adults with a BMI of 30 or above. Whether any particular dose is appropriate is a clinical decision; it is not something to adjust independently.

It helps to treat each pen as its own chapter. Appetite suppression builds gradually, and expecting dramatic changes in the first few weeks tends to lead to frustration. A question our prescribers hear regularly is whether the medicine is working yet, the honest answer is that it is doing the quieter job of preparation first. The Wegovy user guide on this site walks through each stage in more detail.

Step 2: Managing the side effects Wegovy users most commonly report

Nausea is the side effect that gets the most attention, and for good reason, it affects a meaningful proportion of users, especially after dose increases. It tends to arrive in the first day or two after an injection and then fade before the next one is due. Eating smaller portions, slowing down at meals and staying well hydrated all help. Constipation, loose stools, indigestion and fatigue round out the GI profile for most people.

Serious side effects are less common but genuinely matter. In January 2026 the MHRA updated its safety guidance on GLP-1 medicines to highlight acute pancreatitis as an infrequent but serious risk. If you develop severe, persistent stomach pain that spreads towards your back (with or without vomiting) stop the injection and get medical help the same day. This is not a typical nausea episode. Gallbladder problems are another recognised risk worth knowing about, as is dehydration if a vomiting episode runs for longer than a day or two.

If you are on oral contraceptives, it is worth knowing that the NHS notes no equivalent evidence of reduced pill absorption with semaglutide, unlike tirzepatide. That said, any changes to other medicines should always be discussed with your prescriber. You can explore whether supplements are appropriate alongside semaglutide if that is something on your mind.

Step 3: Building the routines that make Wegovy work

Wegovy is a once-weekly injection, and consistency on the same day each week helps keep the medicine's level stable. Most people pick a day that fits around their routine (Sunday evenings, Monday mornings) and stick to it. The pen is stored in the fridge, typically on the door shelf, which makes it easy to spot and keeps the medicine within its required 2 to 8°C range. If you are ever unsure about a storage window away from refrigeration, the Patient Information Leaflet that comes with the pen has the exact guidance; never rely on a general estimate.

Injection sites rotate between the abdomen, thigh and upper arm, with each session in a different spot to avoid local reactions. How to inject Wegovy correctly is covered step by step for anyone who is new to self-injection or wants to check their technique. The pen itself is pre-filled and does not require any assembly, the needle is concealed and the mechanism locks automatically after use.

Lifestyle changes matter alongside the medicine. The NHS semaglutide information page is clear that Wegovy is licensed as an adjunct to a reduced-calorie diet and increased physical activity, not a replacement for them. Protein intake, hydration and keeping active all become more relevant once appetite is reduced, because eating less does not automatically mean eating well. Many users find that the appetite change is the opening, not the answer on its own.

Step 4: What the evidence says and what it does not promise

The STEP 1 clinical trial, published in the New England Journal of Medicine, followed adults with obesity using semaglutide 2.4 mg for 68 weeks alongside lifestyle intervention and reported an average body-weight reduction of around 15%. That is an average across a large group, individual results varied, and some people responded much more, others less so. Framing Wegovy as a guaranteed outcome misreads both the trial and how the medicine works.

NICE recommends semaglutide for weight management in adults with a BMI of 35 or above and at least one weight-related condition, used within a specialist multidisciplinary service for a maximum of two years. Private treatment through a regulated online pharmacy operates under the licensed eligibility criteria in the product's SmPC, which is broader (BMI of 30 or above, or 27 or above with a qualifying condition) and has no two-year time limit imposed by NICE. You can read more about the full picture of Wegovy in the UK or look at how the cost of Wegovy treatment is structured before deciding on your next step.

If you are weighing Wegovy against other options, the weight-loss treatment overview covers what is currently licensed. And if you are already on treatment and want to hear from others in a similar position, the Wegovy users forum is a space for shared experience. When you are ready to speak to a prescriber directly, start your free consultation with the nume clinical team.